



**RPG LIFE SCIENCES LIMITED**

October 21, 2016

To,

National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department  
Floor 25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

Dear Sirs,

**Sub: Unaudited financial results for the quarter and half year ended September 30, 2016**

**(Scrip Code: RPGLIFE / 532983)**

Please find enclosed herewith a copy of Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2016 which was approved by the Board of Directors at its meeting held on October 21, 2016 along with the Limited Review Report by the Statutory Auditors of the Company.

The meeting commenced at 3.00 p.m. and concluded at 6.45 p.m.

Kindly take the above on your record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

  
Rajesh Shirambekar  
Head - Legal & Company Secretary



Encl: As above



# RPG LIFE SCIENCES LIMITED

Rs. In Lakhs

STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30th SEPTEMBER, 2016						
Particulars	3 months ended			6 months ended		Year ended
	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
	Unaudited			Unaudited		Audited
1. Income from Operations						
(a) Net Sales/Income from Operations (Net of Excise Duty)	7,638	8,523	6,720	16,161	13,370	27,454
(b) Other Operating Income	222	220	121	442	215	478
Total Income from Operations (Net)	7,860	8,743	6,841	16,603	13,585	27,932
2. Expenses						
(a) Cost of Materials Consumed	1,320	2,034	1,794	3,354	3,105	6,025
(b) Purchases of Stock-in-Trade	1,560	1,786	882	3,346	1,659	3,360
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(44)	(750)	(432)	(794)	(142)	(241)
(d) Employee Benefits Expense	1,863	1,819	1,797	3,682	3,574	7,413
(e) Depreciation and Amortisation Expense	239	268	262	507	517	1,015
(f) Other Expenses	2,494	2,577	2,252	5,071	4,306	9,027
Total Expenses	7,432	7,734	6,555	15,166	13,019	26,599
3. Profit from Operations before Other Income, Finance Costs and Exceptional Items	428	1,009	286	1,437	566	1,333
4. Other Income	18	18	45	36	73	78
5. Profit from Ordinary Activities before Finance Costs and Exceptional Items	446	1,027	331	1,473	639	1,411
6. Finance Costs	18	40	75	58	169	249
7. Profit from Ordinary Activities after Finance Costs but before Exceptional Items	428	987	256	1,415	470	1,162
8. Exceptional Items - Profit on sale of Biotech Business Unit [Refer Note 5]	738	-	-	738	-	-
9. Profit from Ordinary Activities before Tax	1,166	987	256	2,153	470	1,162
10. Tax Expense						
a. Current Tax	250	213	61	463	97	224
b. MAT Credit Entitlement	(250)	(213)	(61)	(463)	(97)	(224)
c. Deferred Tax	141	-	-	141	-	-
11. Net Profit for the period	1,025	987	256	2,012	470	1,162
12. Paid-up Equity Share Capital (Face Value Rs. 8 each)	1,323	1,323	1,323	1,323	1,323	1,323
13. Reserves excluding Revaluation Reserves (as per last audited Balance Sheet)						12,036
14. Earnings per Share (of Rs. 8 each) (not annualised):						
(a) Basic	6.20	5.97	1.55	12.17	2.84	7.03
(b) Diluted	6.20	5.97	1.55	12.17	2.84	7.03



Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India

Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127

E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com

CIN : L24232MH2007PLC169354





# RPG LIFE SCIENCES LIMITED

**Notes:**

**1. Standalone Statement of Assets and Liabilities**

Particulars	(Rs. in lakhs)	
	As at 30.9.2016	As at 31.3.2016
<b>A EQUITY AND LIABILITIES</b>		
<b>1. Shareholders' Funds</b>		
(a) Share Capital	1,323	1,323
(b) Reserves and Surplus	14,048	12,036
<b>Sub-total - Shareholders' Funds</b>	<b>15,371</b>	<b>13,359</b>
<b>2. Non-Current Liabilities</b>		
(a) Long-term Borrowings	24	24
(b) Deferred Tax Liabilities (Net)	141	-
(c) Other Long-term Liabilities	263	261
(d) Long-term Provisions	185	199
<b>Sub-total - Non-Current Liabilities</b>	<b>613</b>	<b>484</b>
<b>3. Current Liabilities</b>		
(a) Short-term Borrowings	1,826	2,196
(b) Trade Payables	4,047	3,371
(c) Other Current Liabilities	766	1,017
(d) Short-term Provisions	320	96
<b>Sub-total - Current Liabilities</b>	<b>6,959</b>	<b>6,680</b>
<b>TOTAL - EQUITY AND LIABILITIES</b>	<b>22,943</b>	<b>20,523</b>
<b>B ASSETS</b>		
<b>1. Non-Current Assets</b>		
(a) Fixed Assets	9,737	11,085
(b) Long-term Loans and Advances	1,025	719
<b>Sub-total - Non-Current Assets</b>	<b>10,762</b>	<b>11,804</b>
<b>2. Current Assets</b>		
(a) Inventories	4,702	3,902
(b) Trade Receivables	4,774	3,699
(c) Cash and Bank Balances	1,863	80
(d) Short-term Loans and Advances	842	1,038
<b>Sub-total - Current Assets</b>	<b>12,181</b>	<b>8,719</b>
<b>TOTAL - ASSETS</b>	<b>22,943</b>	<b>20,523</b>

2. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its respective meetings held on 21<sup>st</sup> October, 2016.

3. The results for the quarter ended 30th September, 2016 have been subjected to limited review by the statutory auditors of the Company.

4. The Company is exclusively engaged in the pharmaceuticals segment.

5. Pursuant to the approval of the Board of Directors at their meeting held on May 26, 2016, the Company had entered into a Business Transfer Agreement dated May 26, 2016 with Intas Pharmaceuticals Limited for sale of Biotech Business Unit, as a going concern on a slump sale basis, at a consideration of Rs. 2,487 lakhs. The sale consideration has been received on July 6, 2016 (closing date). The gain realised from the aforesaid sale of Biotech Business Unit amounting to Rs. 738 lakhs has been disclosed as an exceptional item in the financial results. The same has been considered as discontinuing operations in accordance with Accounting Standard - 24 "Discontinuing Operations" and the requisite information for Biotech Business Unit has been furnished hereunder;

Particulars	Rs. In Lakhs					
	3 months ended			6 months ended		Year ended
	30.09.2016	30.06.2016	30.09.2015	30.09.2016	30.09.2015	31.03.2016
	Unaudited					Audited
a) Net Sales	-	643	508	643	927	2,437
b) Direct Expenses	(7)	496	558	489	1,006	2,114
c) Profit/(Loss) from ordinary activities before tax	7	147	(50)	154	(79)	323
d) Tax Expense (net off MAT Credit Entitlement)	-	-	-	-	-	-
e) Net Profit/(Loss) from ordinary activities after tax (c-d)	7	147	(50)	154	(79)	323
f) Profit on sale of Biotech Business Unit	738	-	-	738	-	-
g) Tax Expense [net of MAT credit entitlement] on f) above	-	-	-	-	-	-
h) Profit on sale of Biotech Business Unit (net of tax) (f-g)	738	-	-	738	-	-
i) Net Profit/(Loss) from discontinuing operations (e+h)	745	147	(50)	892	(79)	323

Particulars	(Rs. in lakhs)	
	As at 30.9.2016	As at 31.3.2016
Unaudited		
<b>A Assets</b>	-	2,502
<b>B Liabilities</b>	-	739

6. The Company has entered into an Asset Purchase Agreement (APA) dated July 27, 2016 for purchase of Trademarks on assignment/perpetual license basis and other assets specified in the said APA from Sun Pharmaceutical Industries Limited (including its subsidiary, Sun Pharma Laboratories Limited) for a consideration of Rs.4,100 lakhs (excluding value of specified inventories on closing to be acquired at agreed price). The closing date being October 21, 2016, no effect of the aforesaid APA has been given in the financial result for the current quarter.

7. Figures for the prior periods have been regrouped where necessary.



For RPG Life Sciences Limited

CT. Renganathan  
Managing Director  
Mumbai, 21<sup>st</sup> October, 2016



Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai 400030, India

Tel: +91-22-24981650 / 66606375 ♦ Fax: +91-22-24970127

E-mail : info@rpglifesciences.com ♦ Web: www.rpglifesciences.com

CIN : L24232MH2007PLC169354



The Board of Directors  
RPG Life Sciences Limited  
RPG House  
463, Dr. Annie Besant Road,  
Worli, Mumbai – 400 030

1. We have reviewed the unaudited financial results of RPG Life Sciences Limited (the “Company”) for the quarter ended September 30, 2016 which are included in the accompanying ‘Statement of Standalone Unaudited Results for the quarter and half year ended 30th September, 2016’ and the statement of assets and liabilities as on that date (the “Statement”). The Statement has been prepared by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the “Listing Regulations, 2015”), which has been initialled by us for identification purposes. The Statement is the responsibility of the Company’s management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.
3. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the Statement has not been prepared in all material respects in accordance with the applicable Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognised accounting practices and policies, and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Lovelock & Lewes  
Firm Registration Number: 301056E  
Chartered Accountants



Sumit Seth  
Partner  
Membership Number 105869

Mumbai  
21<sup>st</sup> October, 2016